Alzecure Pharma’s Q4’20 report (published last week) summarized a year where the company advanced across its pipeline and reported milestones according to plan. Even though we see no major milestones (except a partner deal that serves as a joker for this exciting early-stage biotech) occurring in 2021, it will be equally important to continue steady progress and its transition into a fully-fledged development organization. In this update, we deep-dive onto the news flow investors could expect and go through the key changes we have made that have led to a new Base Case.